Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Fundamental Analysis

NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD

9.44  -0.25 (-2.58%)

After market: 11 +1.56 (+16.53%)

Fundamental Rating

3

Taking everything into account, RNAZ scores 3 out of 10 in our fundamental rating. RNAZ was compared to 556 industry peers in the Biotechnology industry. RNAZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RNAZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

RNAZ had negative earnings in the past year.
RNAZ had a negative operating cash flow in the past year.
RNAZ had negative earnings in each of the past 5 years.
RNAZ had a negative operating cash flow in each of the past 5 years.
RNAZ Yearly Net Income VS EBIT VS OCF VS FCFRNAZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

RNAZ's Return On Assets of -193.60% is on the low side compared to the rest of the industry. RNAZ is outperformed by 88.13% of its industry peers.
RNAZ's Return On Equity of -248.18% is on the low side compared to the rest of the industry. RNAZ is outperformed by 70.14% of its industry peers.
Industry RankSector Rank
ROA -193.6%
ROE -248.18%
ROIC N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAZ Yearly ROA, ROE, ROICRNAZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

RNAZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAZ Yearly Profit, Operating, Gross MarginsRNAZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

6

2. Health

2.1 Basic Checks

RNAZ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RNAZ has more shares outstanding
RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNAZ Yearly Shares OutstandingRNAZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
RNAZ Yearly Total Debt VS Total AssetsRNAZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

RNAZ has an Altman-Z score of -9.30. This is a bad value and indicates that RNAZ is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RNAZ (-9.30) is worse than 71.58% of its industry peers.
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.3
ROIC/WACCN/A
WACCN/A
RNAZ Yearly LT Debt VS Equity VS FCFRNAZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 5.20 indicates that RNAZ has no problem at all paying its short term obligations.
With a Current ratio value of 5.20, RNAZ perfoms like the industry average, outperforming 54.68% of the companies in the same industry.
A Quick Ratio of 5.20 indicates that RNAZ has no problem at all paying its short term obligations.
With a Quick ratio value of 5.20, RNAZ perfoms like the industry average, outperforming 55.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
RNAZ Yearly Current Assets VS Current LiabilitesRNAZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

3

3. Growth

3.1 Past

RNAZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.31%, which is quite impressive.
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
Based on estimates for the next years, RNAZ will show a very strong growth in Revenue. The Revenue will grow by 147.39% on average per year.
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%

3.3 Evolution

RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2028 2029 2030 10M 20M 30M 40M 50M
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200K -400K -600K -800K -1M

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNAZ. In the last year negative earnings were reported.
Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAZ Price Earnings VS Forward Price EarningsRNAZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAZ Per share dataRNAZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K

4.3 Compensation for Growth

A more expensive valuation may be justified as RNAZ's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.99%

0

5. Dividend

5.1 Amount

RNAZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (7/22/2025, 8:00:01 PM)

After market: 11 +1.56 (+16.53%)

9.44

-0.25 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/amc
Earnings (Next)N/A N/A
Inst Owners9.46%
Inst Owner Change0%
Ins Owners0.15%
Ins Owner Change0%
Market Cap7.84M
Analysts82.86
Price TargetN/A
Short Float %8.51%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1462.72
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-15.08
FCFYN/A
OCF(TTM)-15.05
OCFYN/A
SpS0
BVpS12.4
TBVpS12.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.6%
ROE -248.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-273.44%
ROA(5y)-214.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -9.3
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)45.08%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.58%
EPS Next Y99.7%
EPS Next 2Y41.41%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.39%
EBIT growth 1Y12.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.47%
OCF growth 3YN/A
OCF growth 5YN/A